Article Type : Case Report
Authors : Abdelrahman A, Bilali A, Ahmed M, Vadkout M, Syed S, Nair D, Faisal B, Gupta P and Chetty D
Keywords : Steroids/Plasma Exchange; Monoclonal Antibodies; Rituximab
TTP is a life-threatening disorder in which the blood clots that form in the small blood vessels throughout the body can limit or block blood flow to the major organs. This, in turn, can damage the organs like the brain, kidneys, and heart and prevent them from functioning correctly. Here, we present a case of a 52-year-old he experienced abdominal pain, mild fever and thrombocytopenia. Things took a serious turn when, he developed seizures altered conscious level, hemiplegia and worsening of thrombocytopenia, he was electively intubated and was on mechanical ventilation till stabilization and improving symptoms.
TTP can affect any organ system, but involvement
of the peripheral blood, the central nervous system, and the kidneys causes the
clinical manifestations. The classic histologic lesion is one of bland thrombi
in the microvasculature of affected organs. These thrombi consist predominantly
of platelets, with little fibrin and red cells compared with thrombi that occur
secondary to intravascular coagulation.
Patients with thrombotic
thrombocytopenic purpura (TTP) typically report an acute or subacute onset of
the following symptoms related to central nervous system (CNS) dysfunction,
anemia, or thrombocytopenia:
·
Neurologic
manifestations include alteration in mental status, seizures, hemiplegia,
paresthesias, visual disturbance, and aphasia
·
Fatigue may
accompany the anemia
·
Severe bleeding
from thrombocytopenia is unusual, although petechiae are common
Clinical manifestations may also include the
following:
·
Fever occurs in
approximately 50% of patients
·
Patients may
notice dark urine from hemoglobinuria.
Case Presentation
A 52-year-old he presented to
emergency department with complaint of abdominal pain, mild fever further
evaluation he was found to have thrombocytopenia anaemia and renal impairment
suddenly patient developed altered conscious level, hemiplegia and seizures, and
was intubated electively and connected to mechanical ventilation. In view of
laboratory tests which shows sever thrombocytopenia, anaemia and renal
impairment. MRI brain which shows cerebral odema and suspicion of PRESS.
Thrombotic Thrombocytopenia Purpura (TTP) – a rare disorder of the blood
coagulation system that usually affects 4-6 persons per million population- was
suspected and The ADAMTS 13 test confirmed he had TTP, a rare disease that can
be fatal if left untreated. We started Pulse steroid /Plasma exchange and rituximab
to rapidly control this blood crises Patient remained hemodynamically unstable
and critical under mechanical ventilation and deep sedation to avoid worsening
of neurological status .After multiple PLEX and rituximab doses platelet count
improved and patient successfully weaned of mechanical ventilation. Patient
later extubated and becomes fully conscious oriented laboratory results become
better [1-9].
Investigations
N-terminal pro B-type natriuretic
peptide 168.20 pmol/lit. Troponin T (High Sensitive) 172.60 pgram/mil. Lactate
Dehydrogenase 1472 iu/lit. Lipase 181.20 iu/lit. Hb 8.0 gram/deciliter. Ht
21.90%. Platelets 11000. Blood smear, peripheral: Findings are suggestive of
hemolytic anemia with severe thrombocytopenia, probably of microangiopathic
hemolytic. ADAMTS13 ACTIVITY less than 2.0%, ADAMTS13 ANTIBODY 65 units per
milliliter, Creatinine 199 mmol/ml, Haptoglobin report was 0.03 g/lit .Urea
Nitrogen 19.80 mmol/lit. USG abdomen possiblity of medical renal disease,
bilateral renal cyst. CT abdomen was suggestive of acute pancreatitis.
Management
A 12-member multi-disciplinary team
of doctors to analyze his health condition and plan the next steps. The team
designed the treatment protocol and started therapeutic plasma exchange (TPE) –
a process of replacement of plasma obtained from healthy individuals. The
patient received a total of 10 sessions of TPE daily with almost 30 litres of
plasma exchanged. He was also treated with steroids (high dose
methylprednisolone 1G IV daily for 5 days than 1 mg/kg IV daily) and monoclonal
antibodies. Rituximabis typically given in a dosage of 375 mg/m2
weekly for 4 weeks. Ideally, at least 4 hours should elapse between
administration of rituximab and plasma exchange.
Follow up
The patient to be seen every week for
2 weeks, weekly measurement of a complete blood count and lactate dehydrogenase
(LDH) are performed and were good. Regular monitoring of ADAMTS13 activity is
also recommended during follow up of patients ? with TTP in remission. Patient
flyed to home country to continue follow up there.
There is no method of preventing TTP
or its relapse. According to doctors, when a patient is diagnosed with this
disease, it is better to follow a healthy lifestyle by avoiding smoking and
ensuring adequate hydration, a low-carbohydrate, low-salt, low-fat diet, and
proper sleep.
Discussion
Patient was admitted in the Intensive
Care Unit with chief complaint of abdominal pain associated with vomiting and
epigastric tenderness. Patient was suspected to have acute pancreatitis. Blood
smear were suggestive of hemolytic anemia with sever thrombocytopenia, probably
of microangiopathyic hemolytic anaemia. In view of severe thrombocytopenia and
active hemolysis, need for Therapeutic Plasma exchange was explained to the
patient. Patient developed altered sensorium and convulsions and developped
MODs, So poor prognosis.
Patient was connected to mechanical
ventilation and deeply sedated. ADAM TS13 and ADAM 13 antibody was sent, which
came back positive. Patient was diagnosed to have Thrombotic Thrombocytopenic
Purpura as per the finding and guidelines. The International Society on
Thrombosis and Haemostasis (ISTH) issued guidelines on the treatment of TTP in
2020. For the treatment of a first acute event, the panel suggests the addition
of rituximab to corticosteroids and TPE, So Patient was continued on
plasmapheresis therapy, intravenous high dose of steroids, the anti-CD20
monoclonal antibody rituximab, antiepileptics and supportive care. Patient
respond later MODs corrected and platelets count improved. Proper weaning and
later successful extubation from mechanical ventilation done.
Conclusion
Management of life threatening
Thrombotic Thrombocytopenia Purpura (TTP) complicated with multiorgan
dysfunction syndrome and sequelae is life threatening condition, this require
multidisciplinary team approach to control multiple organ dysfuction/failure.
Treatment of the first acute event, using rituximab, corticosteroids and TPE
shows efficacy in inducing remission.
1.
Stanley M, Killeen
RB, Michalski JM. Thrombotic Thrombocytopenic Purpura. 2023.
2.
Sukumar S, Lämmle
B, Cataland SR. Thrombotic Thrombocytopenic Purpura: Pathophysiology,
Diagnosis, and Management. J Clin Med. 2021; 10.
3.
Cauchois R, Muller
R, Lagarde M, Dignat-George F, Tellier E, Kaplanski G. Is Endothelial
Activation a Critical Event in Thrombotic Thrombocytopenic Purpura?. J Clin
Med. 2023; 12.
4.
Mariotte E,
Azoulay E, Galicier L, Rondeau E, Zouiti F, Boisseau P, et al. Epidemiology and
pathophysiology of adulthood-onset thrombotic microangiopathy with severe
ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional
analysis of the French national registry for thrombotic microangiopathy. Lancet
Haematol. 2016; 3: e237-245.
5.
Scully M, Thomas
M, Underwood M, Watson H, Langley K, Camilleri RS, et al. Thrombotic
thrombocytopenic purpura and pregnancy: presentation, management, and
subsequent pregnancy outcomes. Blood. 2014; 124: 211-219.
6.
Markham-Lee Z,
Morgan NV, Emsley J. Inherited ADAMTS13 mutations associated with Thrombotic
Thrombocytopenic Purpura: a short review and update. Platelets. 2023; 34:
2138306.
7.
Scully M, Cataland
SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, et al. Caplacizumab
Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2019;
380: 335-346.
8.
Schofield J,
Hosseinzadeh S, Burton K, Pavord S, Dutt T, Doree C, et al. Drug-induced
thrombotic thrombocytopenic purpura: A systematic review and review of European
and North American pharmacovigilance data. Br J Haematol. 2023; 201: 766-773.
9.
Wu N, Liu J, Yang
S, Kellett ET, Cataland SR, Li H, et al. Diagnostic and prognostic values of
ADAMTS13 activity measured during daily plasma exchange therapy in patients
with acquired thrombotic thrombocytopenic purpura. Transfusion. 2014.